# ALOX5 Expression and Pathomics Features Reveal New Insights Into Lung Adenocarcinoma Prognosis: Model Construction and Functional Validation

**Authors:** Peihong Hu, Chun Huang, Xin Liu, Qiang Li, Run Xiang, Xu Liang

PMC · DOI: 10.1155/humu/3303601 · Human Mutation · 2026-03-09

## TL;DR

This study explores how ALOX5 expression and pathomics features can predict lung adenocarcinoma prognosis and improve patient outcomes.

## Contribution

A novel pathomics-based model is developed to predict ALOX5 expression and prognosis in lung adenocarcinoma.

## Key findings

- Elevated ALOX5 and pathomics scores correlate with improved survival in LUAD patients.
- The GBM pathomics model achieved strong predictive performance with AUCs of 0.786 and 0.741 in training and validation sets.
- ALOX5 knockdown in cells increased tumor proliferation and migration, confirming its functional role.

## Abstract

Arachidonic acid 5‐lipoxygenase (ALOX5) is a biomarker of lung adenocarcinoma (LUAD). This research seeks to establish a prognostic model for LUAD by examining ALOX5 expression.

The Cancer Genome Atlas database provided the pathological images and transcriptome data. To determine the prognostic value of ALOX5, survival analysis and Cox regression (univariate and multivariate) were conducted, along with subgroup analysis and interaction tests. The OTSU algorithm and the PyRadiomics package were used to segment the pathological images of patients with LUAD and extract pathological features. The gradient‐enhanced model algorithm was used to construct the pathological omics model. The prognostic value of pathomics mechanism analysis was confirmed using the pathomics score (PS) output from the model. Cell experiments were used to verify gene function.

A total of 327 samples and seven best pathological features were included in the analysis. In LUAD, elevated levels of ALOX5 and PS were associated with improved overall survival. The gradient boosting machine (GBM) pathomics model demonstrated strong predictive performance and clinical applicability, achieving an area under the curve (AUC) of 0.786 in the training set (n = 230) and 0.741 in the validation set (n = 97). According to the model, samples with elevated ALOX5 expression exhibited higher PS values. Moreover, macrophage infiltration was significantly increased in groups with high PS expression. Gene set enrichment analysis (GSEA) indicated that genes differentially expressed between PS subgroups were involved in apoptosis and inflammatory‐response pathways. Apoptosis‐related genes were positively correlated with PS values (p < 0.001), and 63 hub genes associated with the inflammatory response were enriched in cytokine‐mediated signaling pathways. In vitro experiments showed that ALOX5 knockdown in lung cancer cells enhanced tumor cell proliferation and migration.

There was a strong link between ALOX5 expression levels and OS in LUAD patients. A pathomics‐based model can effectively predict the expression level of ALOX5; as a result, LUAD patients′ prognoses can be predicted.

## Linked entities

- **Genes:** ALOX5 (arachidonate 5-lipoxygenase) [NCBI Gene 240]
- **Diseases:** lung adenocarcinoma (MONDO:0005061)

## Full-text entities

- **Genes:** FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, DPEP2 (dipeptidase 2) [NCBI Gene 64174] {aka MBD2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, PIK3R5 (phosphoinositide-3-kinase regulatory subunit 5) [NCBI Gene 23533] {aka F730038I15Rik, FOAP-2, P101-PI3K, p101}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, LOX (lysyl oxidase) [NCBI Gene 4015] {aka AAT10}, ALOX5 (arachidonate 5-lipoxygenase) [NCBI Gene 240] {aka 5-LO, 5-LOX, 5LPG, LOG5}, PIK3CG (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma) [NCBI Gene 5294] {aka IMD97, PI3CG, PI3K, PI3Kgamma, PIK3, p110gamma}
- **Diseases:** death (MESH:D003643), colon cancer (MESH:D015179), necrosis (MESH:D009336), bladder cancer (MESH:D001749), lung cancer (MESH:D008175), Cancer (MESH:D009369), adenocarcinoma (MESH:D000230), inflammation (MESH:D007249), small cell carcinomas (MESH:D018288), gliomas (MESH:D005910), melanoma (MESH:D008545), small cell lung cancer (MESH:D055752), OS (MESH:C567932), non-small cell lung cancer (MESH:D002289), LUAD (MESH:D000077192), gastric cancer (MESH:D013274)
- **Chemicals:** cisplatin (MESH:D002945), CBh (-), H&amp;E (MESH:D006371), crystal violet (MESH:D005840), hematoxylin (MESH:D006416), penicillin (MESH:D010406), puromycin (MESH:D011691), eosin (MESH:D004801), PVDF (MESH:C024865), formalin (MESH:D005557), BCA (MESH:C047117), carbon dioxide (MESH:D002245), lipid (MESH:D008055), paraformaldehyde (MESH:C003043), streptomycin (MESH:D013307), paraffin (MESH:D010232), SDS (MESH:D012967), iron (MESH:D007501)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** PC9 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_B260), RM02823 — Homo sapiens (Human), Transformed cell line (CVCL_IA40), H2170 — Homo sapiens (Human), Lung squamous cell carcinoma, Cancer cell line (CVCL_1535), HCC827 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_2063), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), CCK-8 — Homo sapiens (Human), T-cell prolymphocytic leukemia, Cancer cell line (CVCL_5443), HBE — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_AR51), H23 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1547), RK21203 — Rattus norvegicus (Rat), Finite cell line (CVCL_A9IP), H1975 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1511), H1299 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0060), H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968730/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12968730/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968730/full.md

---
Source: https://tomesphere.com/paper/PMC12968730